BioAge Labs是一家开发抗老年治疗的公司, 面对分析师将库存降为“销售”。 BioAge Labs, a company developing anti-aging treatments, faces a stock downgrade to "sell" by analysts.

BioAge Labs 是一家通过针对衰老开发肥胖等代谢疾病疗法的公司，其股票评级已被华尔街禅宗从“持有”下调至“卖出”。 BioAge Labs, a company developing therapies for metabolic diseases like obesity by targeting aging, has seen its stock rating downgraded to "sell" from "hold" by Wall Street Zen. 该公司的股份在过去一年的2.88美元和26.62美元之间浮动,于星期五以4.13美元开放。 The company's shares, which have fluctuated between $2.88 and $26.62 over the past year, opened at $4.13 on Friday. BioAge利用先进技术查明基于与老龄化有关的分子变化的潜在处理方法。 BioAge uses advanced technology to identify potential treatments based on aging-related molecular changes.